×
About 2,113 results

ALLMedicine™ Photosensitivity Center

Research & Reviews  598 results

Recent Advances in Photodynamic Imaging and Therapy in Hepatobiliary Malignancies: Clin...
https://doi.org/10.3390/curroncol28050345
Current Oncology (Toronto, Ont.); Nanashima A, Hiyoshi M et. al.

Oct 23rd, 2021 - The therapeutic and diagnostic modalities of light are well known, and derivative photodynamic reactions with photosensitizers (PSs), specific wavelengths of light exposure and the existence of tissue oxygen have been developed since the 20th cent...

Exacerbation of eyelid myoclonia in patients with epilepsy and eyelid myoclonia receivi...
https://doi.org/10.1684/epd.2021.1338
Epileptic Disorders : International Epilepsy Journal With... Zawar I, Franic L et. al.

Oct 14th, 2021 - Epilepsy with eyelid myoclonia or Jeavons Syndrome (JS) is a childhood genetic generalized epilepsy. Its clinical features include eyelid myoclonia (hallmark) with or without brief absences, eyelid closure-induced seizures and/or electroencephalog...

The quantitative effect of blue lenses on pediatric photoparoxysmal response - An elect...
https://doi.org/10.1016/j.seizure.2021.09.022
Seizure Strzelecka J, Skadorwa T et. al.

Oct 14th, 2021 - To determine and quantify the effect of blue lenses (Z1) on photosensitivity (PS) suppression in patients aged 5-18 years with and without epilepsy. The retrospective cohort study was carried out in 100 pediatric patients aged 5-18 years with grad...

Efficacy of color lenses in abolishing photosensitivity: Beyond the one-type-fits-all a...
https://doi.org/10.1016/j.yebeh.2021.108332
Epilepsy & Behavior : E&B; Checa-Ros A, Kasteleijn-Nolst Trenite D et. al.

Oct 8th, 2021 - Red-light filtering lenses represent an additional option to medication in photosensitive epilepsy. Blue lenses (Clarlet Z1 F133) can dramatically reduce seizure frequency, with a substantial restriction in luminance that can limit their applicabi...

Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects
https://clinicaltrials.gov/ct2/show/NCT04520217

Oct 5th, 2021 - The purpose of this study is three-fold. First, researchers will assess whether subjects who have clinically abnormal reactions to sunlight (photosensitivity) have increased levels of microvesicle particles (MVP) following ultraviolet B (UVB) trea...

see more →

Drugs  145 results see all →

Clinicaltrials.gov  17 results

Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects
https://clinicaltrials.gov/ct2/show/NCT04520217

Oct 5th, 2021 - The purpose of this study is three-fold. First, researchers will assess whether subjects who have clinically abnormal reactions to sunlight (photosensitivity) have increased levels of microvesicle particles (MVP) following ultraviolet B (UVB) trea...

Tofacitinib in Prevention of Photosensitivity in Lupus
https://clinicaltrials.gov/ct2/show/NCT05048238

Sep 17th, 2021 - Exposure to ultraviolet (UV) rays is a common trigger for increased disease activity (flare) of both cutaneous lupus and systemic lupus. These flares can include rashes, fever, fatigue, joint pain, and other symptoms. The purpose of this clinical ...

Trem-1 and Ultraviolet Radiation-induced Immune Suppression
https://clinicaltrials.gov/ct2/show/NCT05020496

Aug 25th, 2021 - Sunlight is the major environmental agent to which the skin is exposed. Injudicious exposure to wavelengths in the ultraviolet spectrum can lead to sunburn, aging of the skin, skin cancer and a variety of photosensitivity diseases, many of which h...

Effect of Oral Cimetidine in the Protoporphyrias
https://clinicaltrials.gov/ct2/show/NCT05020184

Aug 25th, 2021 - Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are genetic defects of heme biosynthesis that cause life-long, painful cutaneous sensitivity to light. EPP and XLP, collectively called the protoporphyrias, result in the accumu...

Photoprovocation Testing in Subjects With Cutaneous Lupus
https://clinicaltrials.gov/ct2/show/NCT01516788

Jul 13th, 2021 - Photosensitivity is well documented among lupus patients and is one of the diagnostic criteria for systemic lupus erythematosus (SLE). Photosensitivity is highly prevalent in lupus and has a wide range of clinical presentations. However, photosens...

see more →

News  85 results

High Citrus Consumption May Increase Melanoma Risk
https://www.medscape.com/viewarticle/948676

Apr 5th, 2021 - Takeaway High citrus consumption was associated with a significantly increased risk of melanoma. Consumption of oranges and orange juice showed an independent association with the risk of melanoma. Why this matters Findings support previous eviden...

Treatment-Related Toxicity in Advanced MTC
https://www.onclive.com/view/treatment-related-toxicity-in-advanced-mtc

Apr 2nd, 2021 - For High-Definition, Click Unique side effects are associated with each drug approved to treat patients with metastatic medullary thyroid cancer (MTC). As antiangiogenic agents, both vandetanib and cabozantinib are associated with hypertension, ...

Treatment Sequencing in BRAF+ Metastatic Melanoma
https://www.onclive.com/view/treatment-sequencing-in-braf-metastatic-melanoma

Apr 2nd, 2021 - Transcript: Ryan J. Sullivan, MD: The only way you ever know if one regimen is better than another is to compare them head to head. In the absence of comparing head to head, you use lots of ancillary data. There’s a lot of extrapolation involv...

BRAF/MEK Frontline Therapy in Metastatic Melanoma
https://www.onclive.com/view/braf-mek-frontline-therapy-in-metastatic-melanoma

Apr 2nd, 2021 - Transcript: Ryan J. Sullivan, MD: In patients with metastatic melanoma who have a BRAF mutation, there are a number of options, and those options include BRAF-targeted therapy. Those options include anti—PD-1 [anti–programmed cell death protein...

Treating Melanoma Patients With BRAF/MEK Dual-Targeted Therapy
https://www.onclive.com/view/treating-melanoma-patients-with-braf-mek-dual-targeted-therapy

Apr 2nd, 2021 - Transcript: Ryan J. Sullivan, MD: I was an investigator on the phase I trial of the combination of encorafenib and binimetinib. And so I’ve seen the adverse effects in the efficacy outcomes from all hosts of the various different doses of encor...

see more →